Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 698

Sort by

Sort Order Select

Journal Articles

CircPCMTD1 : A Protein-Coding Circular RNA That Regulates DNA Synthesis in Leukemic Myeloblasts

Dimitrios Papaioannou, MD, Remi Buisson, Andreas Petri, PhD, Allison Walker, Marius Bill, MD PhD, Felice Pepe, PhD, Deedra Nicolet, MS, Lauren A Woodward, Krzysztof Mrózek, MD PhD, Malith Karunasiri, Gregory K. Behbehani, MD PhD, Emanuele Cocucci, PhD, Guramrit Singh, PhD, Sakari Kauppinen, PhD, Adrienne M. Dorrance, PhD, Clara D. Bloomfield, MD, Ramiro Garzon, MD

Blood (2019) 134 (Supplement_1): 640.

https://doi.org/10.1182/blood-2019-126223

Published: 2019

Journal Articles

Onset of Regulatory B Cells Occurs at Initial Stage of B Cell Dysfunction in Multiple Myeloma

Zhongqing Zou, Tingting Guo, Jian Cui, Li Zhang, Ling Pan

Blood (2019) 134 (Supplement_1): 1780.

https://doi.org/10.1182/blood-2019-128703

Published: 2019

Journal Articles

Blocking Lysosomal Two-Pore Channel 2 Function Inhibits Proliferation of Multidrug Resistant Leukemia Cells and Sensitizes Them to Vincristine Treatment

Martin Müller, MSc, Franz Geisslinger, Susanne Gerndt, Ramona Schütz, Yu-Kai Chao, Franz Bracher, Christian Grimm, Angelika Vollmar, Karin Bartel

Blood (2019) 134 (Supplement_1): 2081.

https://doi.org/10.1182/blood-2019-128195

Published: 2019

Journal Articles

In Vivo Efficacy of Anti-CD20-Interferon-Gamma Fusion Protein Against Syngeneic B Cell Lymphoma Is Mediated By Natural Killer Cells

Alex Vasuthasawat, BS, MS, Reiko E Yamada, Kham R Trinh, Neiki Rokni, Sherie L Morrison, PhD, John M. Timmerman, MD

Blood (2019) 134 (Supplement_1): 1575.

https://doi.org/10.1182/blood-2019-131890

Published: 2019

Journal Articles

TR57, an Inhibitor of the Integrated Stress Response, Is Synergistic with Venetoclax Against CLL Cells, Independent of Their TP53 Status

Narjis Fatima, BSMedTech,MPhil, Yandong Shen, BMedSc (Hon) PhD, Kyle R Crassini, MBBS,BSc, Edwin Iwanowicz, PhD, Richard Christopherson, PhDEmeritus Professor, Giles Best, BSc, PhD, Stephen P. Mulligan, PhDFRACP,FRCPA,MBBS

Blood (2019) 134 (Supplement_1): 1735.

https://doi.org/10.1182/blood-2019-132160

Published: 2019

Journal Articles

MCL-1 Inhibitor-Induced Killing of Multiple Myeloma Is Modulated By the Relative Level of Expression of Pro-Survival Members of the BCL-2 Family and the Proto-Oncogene MYC

Andrew Spencer, DM, Tiffany Khong, BSc, PhD, Maoshan Chenn, PhD

Blood (2019) 134 (Supplement_1): 1825.

https://doi.org/10.1182/blood-2019-127843

Published: 2019

Journal Articles

CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells

Ekaterina Kim, MS, Hongying Zhang, MD PhD, Mariela Sivina, Alicia Vaca, PhD, Philip A. Thompson, MBBS, Nitin Jain, MD, Alessandra Ferrajoli, MD, Zeev E. Estrov, MD, Michael J Keating, MBBS, William G. Wierda, MD PhD, William G Rice, PhD, Michael Andreeff, MD PhD, Jan A. Burger, MD PhD

Blood (2019) 134 (Supplement_1): 3051.

https://doi.org/10.1182/blood-2019-124473

Published: 2019

Journal Articles

Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)

Tiziana Vaisitti, PhD, Katti Jessen, PhD, Thanh-Trang Vo, PhD, Mira Ko, Francesca Arruga, PhD, Nicoletta Vitale, PhD, Esteban Braggio, PhD, Arianna Di Napoli, Amy Chadburn, MD, John N. Allan, MD, Richard R. Furman, MD, Langdon L. Miller, Brian J Lanutti, PhD, Silvia Deaglio, MD PhD

Blood (2019) 134 (Supplement_1): 2856.

https://doi.org/10.1182/blood-2019-126827

Published: 2019

Journal Articles

Effects of Rifaximin on Intestinal Pathophysiologic Changes Associated with Sickle Cell Disease (SCD)

Dibyendu Dutta, PhD, Seah H Lim, MD PhD

Blood (2019) 134 (Supplement_1): 2282.

https://doi.org/10.1182/blood-2019-127043

Published: 2019

Journal Articles

DNA Cytosine-Demethylating Agent 5-Aza-2'-Deoxycytidine Targets Leukemia Cells through Reducing DNA N 6 -Methyladenine

Xiaochang Liu, PhD, Jiuxia Pang, Christopher Seiler, Ryan Kempen, Hao Liu, Aref Al-Kali, MD, Y. Natalia Tretyakova, Mark Litzow, MD, Shujun Liu

Blood (2019) 134 (Supplement_1): 2513.

https://doi.org/10.1182/blood-2019-130490

Published: 2019

Journal Articles

Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)

Anna Kaci, PhD, Emilie Adiceam, Melanie Dupont, Marine Garrido, Jeannig Berrou, Hanane Djamai, Andre Baruchel, Mike Burbridge, Claude Gardin, Herve Dombret, MD PhD, Thorsten Braun, MD

Blood (2019) 134 (Supplement_1): 2631.

https://doi.org/10.1182/blood-2019-125641

Published: 2019

Journal Articles

PI3Kα/δ Inhibitor, Copanlisib, Inhibits Acute Lymphoblastic Leukemia Cell Growth, Increases Survival and Inhibits CNS Disease Progression in Leukemic Mice

Sarah Ridge, PhD, Hisayuki Yao, PhD, Trevor T Price, PhD, Andrew E Whiteley, PhD, Maegan Burns, Dorothy A. Sipkins, MD

Blood (2019) 134 (Supplement_1): 2758.

https://doi.org/10.1182/blood-2019-132097

Published: 2019

Journal Articles

The Combination of CUDC-907 and Gilteritinib Shows Promising Antileukemic Activity in Vitro and In Vivo in Preclinical Models of FLT3-ITD AML

Tristan Knight, MD, Xinan Qiao, BS, Jun Ma, Holly Edwards, BS, Lisa Polin, PhD, Juiwanna Kushner, Sijana H Dzinic, PhD, Kathryn White, Hai Lin, MD, Yue Wang, Jeffrey W. Taub, MD, Yubin Ge, PhD

Blood (2019) 134 (Supplement_1): 1262.

https://doi.org/10.1182/blood-2019-123793

Published: 2019

Journal Articles

Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way

Blood (2019) 134 (Supplement_1): 4142.

https://doi.org/10.1182/blood-2019-126500

Published: 2019

Journal Articles

ROR1 Targeted Immunoliposomal Delivery of OSU-2S Show Selective Cytotoxicity in t(1;19) Translocated B-ALL

Swagata Goswami, MSc, Chi-Ling Chiang, PhD, Kevan Zapolnik, BS, Zhiliang Xie, James L. Lee, PhD, Sivasubramanian Baskar, Christoph Rader, PhD, John C. Byrd, MD, Mitch A. Phelps, PhD, Bhavana Bhatnagar, DO, Natarajan Muthusamy, DVM,PhD

Blood (2019) 134 (Supplement_1): 3798.

https://doi.org/10.1182/blood-2019-128828

Published: 2019

Journal Articles

Targeting WNT10B-Driven Signalling through Induction of FZD6 By Porcupine Inhibition in T Cell Acute Lymphoblastic Leukemia

Adriana Cassaro, PhD, Francesca Lazzaroni, Dr, Giovanni Grillo, MD, Gianluigi Reda, MD, Roberto Cairoli, MD, Alessandro Beghini

Blood (2019) 134 (Supplement_1): 3956.

https://doi.org/10.1182/blood-2019-124871

Published: 2019

Journal Articles

Isolation and Characterization of a CD34 + Sub-Clone in B-Cell Lymphoma

Ayad Al-Katib, MD, Ebrahim Abdul Shukkur, PhD, Ali M Gabali, MD PhD, ALI Raufi, MD, Salah Ebrahim, MD, Mustapha Kandouz, PhD

Blood (2019) 134 (Supplement_1): 3970.

https://doi.org/10.1182/blood-2019-130738

Published: 2019

Journal Articles

Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment

Yandong Shen, BMedSc (Hon) PhD, Kyle R Crassini, MBBS,BSc, Narjis Fatima, BSMedTech,MPhil, Richard Christopherson, PhDEmeritus Professor, Stephen P. Mulligan, PhDFRACP,FRCPA,MBBS, Oliver Giles Best, PhDBSc

Blood (2019) 134 (Supplement_1): 5443.

https://doi.org/10.1182/blood-2019-130082

Published: 2019

Journal Articles

S100A9 Contributes to T Cell Dysfunction through Its Interaction with RAGE in MDS

Wendy Kandell, BS, Thu Le Trinh, PhD, Xianghong Chen, PhD, Pingyan Cheng, MD, Danielle Gilvary, BS, Yin-Kai Chen, MD, Alexandra Calescibetta, Erika Adriana Eksioglu, MS PhD, Alan F. List, MD, Sheng Wei, MD

Blood (2019) 134 (Supplement_1): 4228.

https://doi.org/10.1182/blood-2019-128717

Published: 2019

Journal Articles

BCL-2 Inhibitor Venetoclax Enhances Temozolomide Sensitivity in AML

Joseph M Brandwein, MD, Asmaa Basonbul, MSc

Blood (2019) 134 (Supplement_1): 2646.

https://doi.org/10.1182/blood-2019-129529

Published: 2019

NARROW

CircPCMTD1 : A Protein-Coding Circular RNA That Regulates DNA Synthesis in Leukemic Myeloblasts

Onset of Regulatory B Cells Occurs at Initial Stage of B Cell Dysfunction in Multiple Myeloma

Blocking Lysosomal Two-Pore Channel 2 Function Inhibits Proliferation of Multidrug Resistant Leukemia Cells and Sensitizes Them to Vincristine Treatment

In Vivo Efficacy of Anti-CD20-Interferon-Gamma Fusion Protein Against Syngeneic B Cell Lymphoma Is Mediated By Natural Killer Cells

TR57, an Inhibitor of the Integrated Stress Response, Is Synergistic with Venetoclax Against CLL Cells, Independent of Their TP53 Status

MCL-1 Inhibitor-Induced Killing of Multiple Myeloma Is Modulated By the Relative Level of Expression of Pro-Survival Members of the BCL-2 Family and the Proto-Oncogene MYC

CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells

Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)

Effects of Rifaximin on Intestinal Pathophysiologic Changes Associated with Sickle Cell Disease (SCD)

DNA Cytosine-Demethylating Agent 5-Aza-2'-Deoxycytidine Targets Leukemia Cells through Reducing DNA N 6 -Methyladenine

Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)

PI3Kα/δ Inhibitor, Copanlisib, Inhibits Acute Lymphoblastic Leukemia Cell Growth, Increases Survival and Inhibits CNS Disease Progression in Leukemic Mice

The Combination of CUDC-907 and Gilteritinib Shows Promising Antileukemic Activity in Vitro and In Vivo in Preclinical Models of FLT3-ITD AML

Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way

ROR1 Targeted Immunoliposomal Delivery of OSU-2S Show Selective Cytotoxicity in t(1;19) Translocated B-ALL

Targeting WNT10B-Driven Signalling through Induction of FZD6 By Porcupine Inhibition in T Cell Acute Lymphoblastic Leukemia

Isolation and Characterization of a CD34 + Sub-Clone in B-Cell Lymphoma

Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment

S100A9 Contributes to T Cell Dysfunction through Its Interaction with RAGE in MDS

BCL-2 Inhibitor Venetoclax Enhances Temozolomide Sensitivity in AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only